News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Dejan Juric

Articles by Dejan Juric

TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

ByDebasish Tripathy,Dejan Juric,Sonia Pernas,Francois Clement Bidard,Kevin Perraud,Louise Emmett,Ana Sofia Ferreira

June 22nd 2025

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

ByMario Campone,Louise Emmett,Dejan Juric,Debasish Tripathy,Sonia Pernas,Monica Zuradelli,Kevin Perraud,Aleix Prat

June 21st 2025

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

ByErika P. Hamilton, MD,Rinath M. Jeselsohn,Sara A. Hurvitz, MD,Dejan Juric,Hyo S Han,Melinda L. Telli, MD,George Zahrah,Rita Nanda, MD,Yuanyuan Zhang,Weiwei Tan,Elizabeth Duperret,Eric Zhi,Cecile Mather,Anne F. Schott, MD

August 10th 2024

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

ByAditya Bardia, MD, MPH, FASCO,Ian E. Krop,Dejan Juric,Takahiro Kogawa,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Toru Mukohara,Takuya Tsunoda,Senthil Damodaran,Funda Meric-Bernstam, MD

April 28th 2023

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

ByKevin Kalinsky, MD, MS,Erika P. Hamilton, MD,Laura Spring,Peter A. Fasching,Sandra Franco, MD,Richard De Boer,Javier Cortes,Dejan Juric,Aditya Bardia, MD, MPH, FASCO,Sina Haftchenary,Agnes Lteif,Juan Pablo Zarate,Liyi Cen,Patrick Neven, MD, PhD

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care

FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC

How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?

EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma

Pre-Cevostamab Treatment May Not Impact Outcomes as Much in Multiple Myeloma

© 2025 MJH Life Sciences^®

All rights reserved.